Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

How I manage CLL with venetoclax-based treatments

William G. Wierda, Francesco Paolo Tambaro

Blood (2020) 135 (17): 1421–1427.

https://doi.org/10.1182/blood.2019002841

Published: 2020

Journal Articles

CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment

Francesco Paolo Tambaro, MD PhD, Clelia Criscuolo, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Philip A Thompson, MBBS, Jan Burger, MD PhD, Zeev Estrov, MD, Mimmo Ripaldi, MD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael Keating, MBBS, William G. Wierda, MD PhD

Blood (2016) 128 (22): 4351.

https://doi.org/10.1182/blood.V128.22.4351.4351

Published: 2016

Journal Articles

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Paolo Strati, Michael J. Keating, Susan M. O'Brien, Jan Burger, Alessandra Ferrajoli, Nitin Jain, Francesco Paolo Tambaro, Zeev Estrov, Jeffrey Jorgensen, Pramoda Challagundla, Stefan H. Faderl, William G. Wierda

Blood (2014) 123 (24): 3727–3732.

https://doi.org/10.1182/blood-2013-11-538116

Published: 2014

Includes: Supplemental data

Journal Articles

A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC

Francesco Paolo Tambaro, MD, PhD, Guillermo Garcia-Manero, MD, Wei Qiao, Sherry A. Pierce, RN, BS, Mimmo Ripaldi, MD, Stefan Faderl, MD, Hagop M Kantarjian, William G. Wierda, MD, PhD, Jorge E Cortes, MD

Blood (2012) 120 (21): 131.

https://doi.org/10.1182/blood.V120.21.131.131

Published: 2012

Journal Articles

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, M.D., Susan O'Brien, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Jorge E. Cortes, MD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, Michael J. Keating, MD, Varsha V. Gandhi, Ph.D.

Blood (2012) 120 (21): 437.

https://doi.org/10.1182/blood.V120.21.437.437

Published: 2012

Journal Articles

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

William G. Wierda, MD, PhD, Kumudha Balakrishnan, Alessandra Ferrajoli, MD, Tapan Kadia, Jorge E. Cortes, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Francesco Paolo Tambaro, MD, PhD, Annette Jalayer, RN, Susan Lerner, MS, BA, Michael J Keating, MD, Varsha Gandhi, PhD

Blood (2011) 118 (21): 3901.

https://doi.org/10.1182/blood.V118.21.3901.3901

Published: 2011

Journal Articles

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, Francesco Paolo Tambaro, MD, PhD, Nebiyou Bekele, Hui Yang, Farhad Ravandi, MD, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, M.D., Ph.D., Stefan Faderl, MD, Jorge E. Cortes, Mark Brandt, BS, Yumin Hu, PhD, Deborah McCue, Willie Mae Newsome, RN, Sherry Pierce, RN, BS, Marcos DeLima, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 763.

https://doi.org/10.1182/blood.V118.21.763.763

Published: 2011

Journal Articles

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

Francesco Paolo Tambaro, MD, PhD, Guillermo Garcia-Manero, Stefan Faderl, MD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Long Xuan Trinh, Susan Lerner, MS, BA, Hagop M. Kantarjian, Michael J Keating, MD, William G. Wierda, MD, PhD

Blood (2011) 118 (21): 981.

https://doi.org/10.1182/blood.V118.21.981.981

Published: 2011

Journal Articles

ROS Activation Independent From Iron Overload in MDS

Francesco Paolo Tambaro, MD, PhD, William G. Wierda, MD, PhD, Sherry Pierce, RN, BS, Hui Yang, MD, PhD, Yue Wei, PhD, Zhihong Fang, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero

Blood (2011) 118 (21): 2798.

https://doi.org/10.1182/blood.V118.21.2798.2798

Published: 2011

Journal Articles

Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Francesco Paolo Tambaro, MD, PhD, Nebiyou Bekele, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Marina Konopleva, MD, PhD, Tapan Kadia, MD, Jorge E. Cortes, Hui Yang, Mark Brandt, BS, Sherry A. Pierce, RN, BS, Willie Mae Newsome, RN, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2189.

https://doi.org/10.1182/blood.V116.21.2189.2189

Published: 2010

Journal Articles

Levels of Nrf2 and Keap1 Are Associated with Poor Prognostic Features In Myelodysplastic Syndromes (MDS)

Francesco Paolo Tambaro, MD, PhD, Carlos Vigil, MD, Yumin Hu, PhD, Hui Yang, MD, PhD, Zhihong Fang, Jack Yu Jia, Hong Zheng, Yue Wei, PhD, Hagop Kantarjian, MD, Lucia Altucci, MD, PhD, Felicetto Ferrara, MD, Guillermo Garcia-Manero, MD

Blood (2010) 116 (21): 1874.

https://doi.org/10.1182/blood.V116.21.1874.1874

Published: 2010

Journal Articles

BARD1: a New Target In Leukemia

Francesco Paolo Tambaro, MD, PhD, Ilaria Lepore, Carmela Dell Aversana, Floriana De Bellis, Marco Miceli, Vincenzo Carafa, Angela Nebbioso, Felicetto Ferrara, MD, Guillermo garcia Manero, MD, Lucia Altucci

Blood (2010) 116 (21): 4642.

https://doi.org/10.1182/blood.V116.21.4642.4642

Published: 2010

Journal Articles

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

Guillermo Garcia-Manero, MD, Francesco Paolo Tambaro, MD, PhD, B. Nebiyou Bekele, PhD, Elias Jabbour, MD, Farhad Ravandi, M.D., Hui Yang, MD, PhD, Gautam Borthakur, MD, Tapan Kadia, MD, Jorge Cortes, MD, Stefan Faderl, MD, Marina Konopleva, MD, PhD, Sherry Pierce, RN, Jan A. Burger, MD, PhD, Zeev Estrov, MD, Susan O'Brien, M.D., Deborah Thomas, Willie Newsome, RN, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1055.

https://doi.org/10.1182/blood.V114.22.1055.1055

Published: 2009

Journal Articles

A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).

Guillermo Garcia-Manero, MD, Daniel R. Couriel, MD, Francesco Paolo Tambaro, MD, PhD, Nashat Gabrail, Ahmed Nadeem, MD, Tapan Kadia, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Stefan Faderl, MD, Willie Newsome, RN, Hui Yang, MD, PhD, Kevin Chen, Karen Stein, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 119.

https://doi.org/10.1182/blood.V114.22.119.119

Published: 2009

NARROW

How I manage CLL with venetoclax-based treatments

CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC

Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy

A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL,

Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

ROS Activation Independent From Iron Overload in MDS

Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Levels of Nrf2 and Keap1 Are Associated with Poor Prognostic Features In Myelodysplastic Syndromes (MDS)

BARD1: a New Target In Leukemia

Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).

A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only